Blood 'fingerprints' for cancer

September 3, 2008

Serum microRNAs (miRNAs) can serve as biomarkers for the detection of diseases including cancer and diabetes, according to research published online this week in Cell Research. The findings pave the way for a revolutionary non-invasive diagnostic tool.

miRNAs are a class of naturally occurring small non-coding RNAs that have been linked with cancer development. Recent studies reporting individual miRNAs as diagnostic biomarkers of specific cancers were unable to rule out the possibility that these miRNAs appeared as a result of contamination.

Chen-Yu Zhang and colleagues are the first to comprehensively characterize entire blood miRNA profiles of healthy subjects and patients with lung cancer, colorectal cancer and diabetes, ruling out contamination. They propose that the specific serum miRNA expression profiles they identified constitute ‘fingerprints’ for cancer and disease.

Although tumour markers greatly improve diagnosis, current diagnostic techniques are prohibitively invasive and therefore have limited clinical application. The new approach is non-invasive and has the potential to transform the clinical management of various cancers and diseases through improving disease diagnosis, cancer classification, prognosis estimation, prediction of therapeutic efficacy, maintenance of surveillance following surgery, and the ability to forecast disease recurrence. The new technique will also be useful to pharmacological companies in identifying population subgroups who are responsive to drugs that have failed in phase III clinical trials.

Source: Nanjing University School of Life Sciences

Explore further: High-fat diet may change breast milk makeup, affect baby's health

Related Stories

High-fat diet may change breast milk makeup, affect baby's health

November 22, 2017
New research suggests that following a high-fat diet during lactation—regardless of diet during pregnancy—alters RNA activity in breast milk. The changes in genetic material may increase the risk of metabolic disorders ...

New blood test developed to diagnose ovarian cancer

October 31, 2017
Investigators from Brigham and Women's Hospital and Dana-Farber Cancer Institute are leveraging the power of artificial intelligence to develop a new technique to detect ovarian cancer early and accurately. The team has identified ...

Exosomes are the missing link to insulin resistance in diabetes

September 21, 2017
Chronic tissue inflammation resulting from obesity is an underlying cause of insulin resistance and type 2 diabetes. But the mechanism by which this occurs has remained cloaked, until now.

Newly discovered microRNA regulates mobility of tumor cells

October 27, 2017
Cancer cells can reactivate a cellular process that is an essential part of embryonic development. This allows them to leave the primary tumor, penetrate the surrounding tissue and form metastases in peripheral organs. In ...

Alterations in blood-based miRNA in veterans affected with combat-related PTSD

September 4, 2017
Individuals affected with PTSD (Post-Traumatic Stress Disorder) demonstrate changes in microRNA (miRNA) molecules associated with gene regulation. A controlled study, involving military personnel on deployment to a combat ...

Development of RNAi-based anti-cancer therapeutics

June 30, 2017
Understanding the interactions between miRNAs with their specific cancer gene targets is an on-going effort to identify new therapeutic strategies. Researchers from University of Malaya carried out investigations to study ...

Recommended for you

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.